Hot flashes refractory to HRT and SSRI therapy but responsive to gabapentin therapy.
There is a need for alternative therapies for hot flashes, as hormone replacement therapy (HRT) is associated with increased rates of breast cancer and heart disease, and some women fail to respond to HRT. A 32-year-old woman with surgically-induced menopause experienced 20-30 severe hot flashes per day and failed to respond to various formulations of HRT and selective serotonin reuptake inhibitor (SSRI) therapy for 17 years. She markedly responded to gabapentin therapy. Gabapentin, SSRIs, and estrogen may act at different cellular targets in the treatment of hot flashes.
Guttuso
Thomas
T
Departmrnt of Neurology, University of Buffalo School of Medicine, 311 Biomedical Research Building, Buffalo, NY 14214, USA.
D000085:Acetates / Q000627:therapeutic use*; D000328:Adult; D000588:Amines; D000927:Anticonvulsants / Q000627:therapeutic use*; D003509:Cyclohexanecarboxylic Acids; D005260:Female; D000077206:Gabapentin; D020249:Hormone Replacement Therapy; D019584:Hot Flashes / Q000188:drug therapy*; D006801:Humans; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D017211:Treatment Failure; D005680:gamma-Aminobutyric Acid
D000085:Acetates; D000588:Amines; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D000077206:Gabapentin; D017367:Selective Serotonin Reuptake Inhibitors; D005680:gamma-Aminobutyric Acid